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Abstract
AIM
To evaluate if any association existed between the 
extent of hepatic necrosis in initial liver biopsies and 
patient survival.
METHODS
Thirty-seven patients with fulminant liver failure, 
whose liver biopsy exhibited substantial necrosis, were 
identified and included in the study. The histological 
and clinical data was then analyzed in order to assess 
the relationship between the extent of necrosis and 
patient survival, with and without liver transplantation. 
The patients were grouped based on the etiology of 
hepatic necrosis. Each of the etiology groups were 
then further stratified according to whether or not they 
had received a liver transplant post-index biopsy, and 
whether or not the patient survived.
RESULTS
The core tissue length ranged from 5 to 44 mm with 
an average of 23 mm. Causes of necrosis included 14 
autoimmune hepatitis, 10 drug induced liver injury 
(DILI), 9 hepatitis virus infection, and 4 unknown origin. 
Among them, 11 showed submassive (26%-75% of the 
parenchymal volume) and 26 massive (76%-100%) 
necrosis. Transplant-free survival was worse in patients 
with a higher extent of necrosis (40%, 71.4% and 
100% in groups with necrosis of 76%-100%, 51%-75% 
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and 26%-50%, respectively). Additionally, transplant-
free survival rates were 66.7%, 57.1%, and 25.0% 
in groups of autoimmune hepatitis, DILI, and viral 
hepatitis, respectively. Even after liver transplantation, 
the survival rate in patients as a result of viral hepatitis 
remained the lowest (80%, 100%, and 40% in groups 
of autoimmune hepatitis, DILI, and viral hepatitis, 
respectively).
CONCLUSION
Adequate liver biopsy with more than 75% necrosis is 
associated with significant transplant-free mortality that 
is critical in predicting survival. 
Key words: Submassive necrosis; Massive necrosis; 
Fulminant liver failure; Liver transplantation; biopsy; 
histopathology
© The Author(s) 2017. Published by baishideng Publishing 
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Core tip: Fulminant liver failure is clinically characterized 
by an abrupt onset of jaundice and liver dysfunction 
with subsequent development of encephalopathy and 
coagulopathy in patients with or without preexisting 
liver disease. Liver biopsy may play a role in predicting 
patient survival, and may also potentially play a role in 
optimizing the utilization of resources in the setting of 
fulminant liver failure.
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INTRODUCTION
Fulminant liver failure is clinically characterized by an 
abrupt onset of jaundice and liver dysfunction with 
subsequent development of encephalopathy and 
coagulopathy in patients with or without preexisting 
liver disease[1-6]. Common etiologies for fulminant 
liver failure include viral hepatitis, autoimmune 
hepatitis, and drug induced liver injury (DILI)[7,8]. 
Other precipitating events comprise alcoholic liver 
disease, ischemia, portal vein thrombosis, and 
infection[9-11]. In some cases, a precipitating factor 
is never identified[9-11]. Regardless of the etiology, 
fulminant liver failure is typically associated with high 
morbidity and mortality[1]. In the clinical setting, the 
grade of encephalopathy has a strong association with 
prognosis[12]. Other prognostic indicators encompass 
coagulation factors (INR or Factor V levels), serum 
bilirubin, transaminases, creatinine, arterial pH, and 
serum lactate[12]. Additionally, computed tomographic 
assessment of liver atrophy is said to be of prognostic 
value[13]. As such, multiple prognostic models (e.g., 
Clichy, King’s College), based mainly on laboratory 
values and clinical findings, have been used to rapidly 
assess the need for transplantation[4,9-12].
Liver biopsy is the gold standard for evaluating 
hepatic diseases. However, these fulminant liver 
failure models do not directly taken into account the 
histopathological findings obtained via liver biopsy. 
Submassive or massive liver necrosis is the worst 
histological finding that is seen in association with 
fulminant liver failure, although it is not seen in every 
biopsy. In fulminant liver failure, the prognosis for 
those with significant hepatic necrosis is generally 
thought to be poor. And yet, the extent of necrosis 
in a biopsy, and its importance in predicting patient 
outcomes, is less well defined in the literature[7,14]. 
One study even casts doubt on the value of hepatic 
necrosis as a prognostic indicator[7].
In this study, we aimed to evaluate if there is any 
association between the degree of hepatocellular 
necrosis and patient survival. Additionally, we attempted 
to identify any relationship between the underlying 
etiology of necrosis and survival. Lastly, we evaluated 
the outcomes of liver transplantation following a histo-
pathological diagnosis of significant hepatic necrosis. 
MATERIALS AND METHODS
Patients and histology
A search of our institution’s pathology database was 
performed in order to retrospectively identify native 
liver biopsies with a diagnosis of either submassive 
or massive hepatic necrosis. Thirty-seven liver biop-
sies, originally performed from 2004 to 2013, were 
identified. The biopsies were distributed among 37 
individual patients who were clinically diagnosed 
with fulminant liver failure. Hepatic necrosis is 
defined as death of hepatocytes, which maybe single 
cell, multiple cells in piecemeal, focal, multifocal, 
submassive or massive (Figure 1). Submassive hepatic 
necrosis is defined as necrosis involving 26%-75% 
of the parenchymal volume, while massive necrosis 
involves more than 75%. The percentage of hepatic 
necrosis is determined based on the total amount of 
necrotic hepatic tissue present vs the amount of total 
parenchyma. Hematoxylin and eosin (H&E) slides 
for each of the individual biopsies were reviewed 
by an experienced pathologist (Lin J) to assess the 
percentage of necrosis and other pathologic features.
A review of each individual patient’s electronic 
medical chart was performed and relevant clinical data 
was obtained. Collected data included age, gender, 
etiology of hepatic necrosis, presence of hepatic 
encephalopathy, whether or not the patient received 
treatment related to the underlying disease, whether 
or not liver transplantation was performed after the 
index liver biopsy, and survival time. Additional clinical 
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information included patient INR values, presence of 
a bacterial infection, and whether or not ascites was 
present. 
The histological and clinical data was then analyzed 
in order to assess the relationship between the extent 
of necrosis and patient survival, with or without liver 
transplantation. Patients were sorted into three groups 
based on the percentage of necrosis present within 
the biopsy (26%-50%, 51%-75%, and 76%-100%). 
Each of the three percentage groups was then further 
stratified according to whether or not they had 
subsequently received a liver transplant. 
A separate analysis of all data was then performed 
in order to assess the relationship between the 
etiology of hepatic necrosis and patient prognosis, 
with or without liver transplantation. The patients 
were grouped based on etiology of hepatic necrosis. 
Etiologies included autoimmune hepatitis, DILI, viral 
hepatitis, and unknown. An unknown etiology was 
defined as any case in which there was no clearly 
identified cause following an extensive clinical workup. 
Each of the etiology groups were then further stratified 
according to whether or not they had received a liver 
transplant post-index biopsy, and whether or not the 
patient survived. 
Statistical analysis
Statistical analysis methodologies included Fisher’s exact 
test and χ2 test. P values of < 0.05 were considered 
statistically significant. All statistics were performed by 
an experienced statistician (Zang Y).
RESULTS
Patients and liver biopsies
The patients within the study ranged in age from 18 
to 75 years old with a mean age of 41 years. Two 
patients were less than 20 years old; 10 were in the 
21-30 year old age group, 4 in the 31-40 age group, 
7 in the 41-50 age group, 6 in the 51-60 age group, 
5 in the 61-70 age group, and 3 patients were older 
than 70. Fourteen (37.8%) were male and 23 (62.2%) 
were female. 
Tissue adequacy for pathologic assessment was 
evaluated. Of 37 liver biopsies, the core tissue length 
ranged from 5 mm to 44 mm with an average of 23 
mm. Twenty-three biopsies (62%) were in the length of 
> 20 mm, 11 (30%) in the range of 10-20 mm , and 3 
(8%) < 10 mm. 
Causes of submassive or massive liver necrosis 
included autoimmune hepatitis in 14 patients, DILI in 
10 (9 due to acetaminophen and 1 due to clopidogrel), 
hepatitis virus infection in 9 patients (1 hepatitis A, 5 
hepatitis B, 2 hepatitis C, and 1 with both hepatitis B 
and C), and unknown origin in 4. All patients within 
the study underwent biopsy with a clinical diagnosis of 
fulminant liver failure. Survival times for all 37 patients 
ranged from less than 1 mo to 127 mo according to 
4305 June 21, 2017|Volume 23|Issue 23|WJG|www.wjgnet.com
A B
C D
Figure 1  Mass and submassive liver necrosis. A: Low power magnification showing complete hepatocellular necrosis in a core biopsy (× 40); B: Medium power 
magnification showing a liver biopsy with perivenular predominant hepatocellular necrosis and intermixed viable hepatocytes located around the portal tract (× 40); 
C: High magnification of image A showing hepatocellular necrosis and profound inflammatory infiltrate in which the architecture of hepatocyte is preserved (× 200); D: 
High magnification of image B reveals the collapse of parenchyma that is replaced by necroinflammatory infiltrate in comparison to the adjacent viable hepatocytes in 
the right upper corner (× 200).
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9 died (mean, 3 mo; range, 1-14 mo after the index 
biopsy). 
In summary, transplant-free survival appeared 
worse in patients with a higher extent of necrosis 
(40%, 71.4% and 100% in groups with necrosis of 
76%-100%, 51%-75% and 26%-50%, respectively). 
Although higher-extent hepatic necrosis appeared to 
be associated with worse prognosis, statistically there 
was no significance between the submassive and the 
massive necrosis groups (P > 0.05). 
Liver transplantation improved patient survival. The 
patients who received liver transplantation appeared 
to have somewhat better survival rates compared 
with non-transplanted patients (100% vs 71.4% 
and 63.6% vs 40.0% in 51%-75% and 76%-100% 
necrosis groups, respectively). However, statistical 
analysis using Fisher’s exact test showed no significant 
difference in the survival rates of patients within the 
transplanted and non-transplanted groups, probably 
due to a small sample size.
Outcome of etiologies causing substantial necrosis 
respective to survival
Further analysis based upon the etiology of substantial 
hepatic necrosis, transplantation status, and survival 
was shown in Table 3. For the 10 cases of drug induced 
hepatic necrosis, only 3 were transplanted and all of 
them survived (100%). Four of the 7 who did not 
receive a transplant survived (57.1%). Overall survival 
rates for DILI group were not statistically different, 
depending on transplantation status (P = 0.475).
Of the 14 cases due to autoimmune hepatitis, 5 
underwent liver transplantation and 4 patients survived 
(80.0%). Six of the 9 patients with autoimmune 
hepatitis who did not receive transplant survived 
(66.7%).Overall survival rates were not significantly 
different, depending on transplantation status (P = 1). 
Five patients within the viral hepatitis group 
underwent transplantation and only 2 survived (40.0%). 
In comparison, only 1 of the 4 viral hepatitis patients 
survived without transplantation (25.0%). Although the 
overall survival rate was higher in the transplant group, 
there was no statistical significance (P = 1).
For the 4 cases of unknown hepatic necrosis, only 1 
patient was transplanted. This patient survived. One of 
the 3 who did not receive a transplant survived. Overall 
survival rates for the unknown group with or without 
transplantation were 100% and 33.3%, respectively. 
Although transplant group had higher survival rate, 
there was no statistical significance (P = 1).
In summary, transplant-free survival rates were 
66.7%, 57.1%, and 25.0% in groups of autoimmune 
hepatitis, DILI, and viral hepatitis, respectively. 
Although the survival rates appeared different among 
the various etiology groups, a statistically significant 
difference only existed between autoimmune hepatitis 
and viral hepatitis groups (P = 0.048). Even after 
the last visit record for each patient. The mean survival 
time was 41 mo.
Ascites, INR, bacterial infection, and hepatic necrosis
As shown in Table 1, the single patient with 26-50% 
necrosis had an INR of 1.34, and no clinical evidence of 
bacterial infection or ascites. Only 1 of the 10 patients 
with 51%-75% necrosis had ascites. The mean INR for 
the patients within this group was 2.19, with individual 
values ranging from 0.95 to 4.52. None of the patients 
within this group had evidence of a bacterial infection. 
Three of the 26 patients with 76%-100% hepatic 
necrosis had a bacterial infection. The mean INR for 
patients in this group was 2.64, with individual values 
ranging from 1.10-5.91. Five of these patients had 
ascites. 
Statistical analysis using Fisher exact test demon-
strated that there was no significant association 
between the presence of ascites and extent of necrosis 
(P = 0.71). Additionally, Fisher’s exact test showed 
no significant association between the presence 
of bacterial infection and extent of necrosis (P = 
0.58). Analysis of variance showed that there was no 
significant association between mean INR level and 
extent of necrosis (P = 0.45).
Outcome of percentage of hepatic necrosis with respect 
to survival 
As shown in Table 2, one patient had 26%-50% 
hepatic necrosis at the time of biopsy. Ten patients had 
51%-75% and 26 patients had 76%-100% necrosis. 
No bridging fibrosis or cirrhosis was appreciated in 
any of them. The patient within the 26%-50% group 
did not receive a transplant and is currently still living 
well with a followup of 86 mo. Out of the 10 patients 
with 51%-75% necrosis, 3 received a liver transplant 
and are still alive (100%) with a mean followup of 86 
mo (range, 66-103 mo). Within this group, 5 of the 
7 who did not receive a transplant are currently still 
living (71.4%) with a mean followup of 72 mo (range, 
21-127 mo) and 2 died (both < 1 mo after the index 
liver biopsy). Within the 76%-100% necrosis group, 
11 underwent liver transplantation; of these, 7 are 
still alive (63.6%) and 4 died. Of the 15 transplant-
free patients within this group, 6 survived (40%) with 
a mean followup of 65 mo (range, 28-122 mo) and 
Table 1  Clinical features of the patients who had submassive 
or massive hepatic necrosis n  (%)
Extent of 
necrosis
Patients 
(n  = 37)
Ascites Bacterial 
infection
INR mean and 
range
26%-50%   1 0 (0) 0 (0) 1.34 (1.34)
51%-75% 10 1 (10) 0 (0) 2.19 (0.95-4.52)
76%-100% 26 5 (19.2) 3 (11.5) 2.64 (1.10-5.91)
The INR data were not available for one patient in the 51%-75% and 
76%-100% groups, respectively.
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liver transplantation, the survival rate in patients as a 
result of viral hepatitis remained the lowest when com-
pared with the other groups, although no statistical 
significance has been reached between DILI and viral 
hepatitis (P = 0.058 or 0.090), or between DILI and 
autoimmune hepatitis (P = 0.116 or 0.408) in the 
setting of transplant or transplant-free, respectively. 
Correlation between hepatic encephalopathy, extent of 
necrosis, transplant and survival 
As demonstrated in Table 4, the patient within 26%-50% 
necrosis group did not have encephalopathy; nor did any 
of the patients within 51%-75% group. Five patients 
within 76%-100% group had encephalopathy (19.2%). 
Thus, it appears that a higher extent of liver necrosis 
is possibly associated with encephalopathy. Further 
analysis of the patients who had encephalopathy 
revealed that the sole surviving patient (10%) within 
this group underwent liver transplantation, with a 
followup time of 92 mo. This finding was statistically 
significant when compared to the transplant-free group 
(57.1%, P < 0.05). 
Of the 21 patients in 76%-100% necrosis group 
without encephalopathy, 10 underwent transplantation, 
and the survival rate was statistically significant 
(60.0%) when compared to the survival rate of 54.5% 
in those who did not undergo transplantation (P < 
0.05). Encephalopathy is an important prognostic 
predictor. The survival rate for transplant-free patients 
with encephalopathy was much lower compared with 
the group without encephalopathy (0% vs 54.5%; P < 
0.05).
DISCUSSION
Studies addressing the prognostic value of liver 
biopsies with substantial necrosis are rare, and the 
conclusions are not well defined in the literature[14,15]. 
Hanau and colleagues questioned the value of hepatic 
necrosis in predicting clinical outcome, because about 
50% of the biopsies in their study showed minimal 
bridging necrosis[7]. In their 1995 study, patients were 
selected based solely on their clinical characteristics 
(e.g., signs and symptoms of fulminant liver failure 
with elevated liver function tests).In contrast, we 
selected and stratified our study cohorts based on 
the extent of necrosis in the liver biopsies. Although 
Hanau’s study included 38 cases, only 12 liver biopsies 
demonstrated either > 90% (3) or 10%-90% (9) 
necrosis. Additionally, Hanau and colleagues found 
that only one of seven (14.3%) patients whose liver 
biopsy demonstrated ≥ 70% necrosis survived without 
transplantation, keeping in line with our finding. In 
another study in 1993, Donaldson and colleagues 
found that only 2 of 19 patients (10.5%) with > 70% 
necrosis survived without transplantation[14]. These 
findings indicate that the percentage of hepatic necrosis 
may be an important prognosticator for patient 
survival. As noted, our transplant-free survival rates are 
much higher with 71.4% and 40% for 51%-75% and 
> 75% necrosis, respectively. A possible explanation 
for the difference in transplant-free survival might be 
related to the different therapeutic options utilized 
in the respective study cohorts. It seems likely that 
some more effective non-transplant related treatments 
Table 2  Prognosis of the patients who had submassive or massive hepatic necrosis with respect to liver transplantation n  (%)
Extent of necrosis Patients (n  = 37) Received transplant (n  = 14) Transplant free (n  = 23)
Died Survived Died Survived
26%-50%   1 NA NA NA 1 (100)
51%-75% 10 NA 3 (100) 2 (28.6) 5 (71.4)
76%-100% 26 4 (36.4)  7 (63.6) 9 (60.0) 6 (40.0)
NA: Not applicable.
Table 3  Prognosis of the patients who had submassive or massive hepatic necrosis with respect to the etiology n  (%)
Etiology Patients (n  = 37) Received transplant (n  = 14) Transplant free (n  = 23)
Died Survived Died Survived
DILI 10 NA 3 (100) 3 (42.9) 4 (57.1)
AIH 14 1 (20.0)  4 (80.0) 3 (33.3) 6 (66.7)
Viral hepatitis   9 3 (60.0)  2 (40.0) 3 (75.0) 1 (25.0)
Unknown   4 NA 1 (100) 2 (66.7) 1 (33.3)
NA: Not applicable; AIH: Autoimmune hepatitis; DILI: Drug induced liver injury.
Table 4  Hepatic encephalopathy with respect to the extent 
of hepatic necrosis n  (%)
Extent of 
necrosis
Patient number 
(n  = 37)
Encephalopathy
Present (n  = 5) Absent (n  = 32)
26%-50%   1 0   1 (100)
51%-75% 10 0 10 (100)
76%-100% 26 5 (19.2)  21 (80.8)
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were available for the patients in our study; as the 
two aforementioned studies took place more than two 
decades ago. Since then, it appears that no report 
has been added in the literature in the regard of 
prognostic value of liver biopsy in an advantaged era 
of liver transplantation for the past 20 years. To the 
best of our knowledge, our study is the largest ever to 
address whether or not there is an association between 
substantial hepatic necrosis and prognosis (11 with 
26%-75% and 26 with > 75% necrosis)[7,14]. Despite 
a difference in approaches between our study, the 
Donaldson study, and the Hanau study, a similar trend 
seems to be present; as the degree of hepatic necrosis 
increases, the transplant-free survival rate declines. 
However, the statistical significance of this trend is still 
not readily apparent, and more studies are certainly 
warranted.
Adequacy is an important matter to consider, 
given the well-known fact that necrosis is often 
heterogeneously distributed throughout the liver[7]. 
The mean core tissue length of 23 mm in our study 
and 21 mm in Donaldson’s[14] study are both adequate. 
Specimen adequacy is not mentioned in Hanau’s 
study[7]. Inadequate biopsy specimens, localized liver 
necrosis[7], and a prolonged interval between the time 
of symptoms and biopsy, are the most common causes 
of a discrepancy between the extent of necrosis in a 
liver biopsy when compared to hepatectomy specimens 
from the same patient (our unpublished data). There-
fore, if a liver biopsy is going to be obtained, it is best 
obtained from a patient where diffuse hepatic necrosis 
is suspected; provided that the biopsy will be adequate 
and is taken as soon as possible following the onset 
of symptoms. Localized liver necrosis due to ischemia 
or other injury can be feasibly monitored by CT/MRI 
imaging, and the interpretation of the biopsy should be 
considered as a local event. 
Importantly, our study has indicated that there may 
be association between etiology and patient survival in 
the setting of submassive or massive necrosis, which 
has not been discussed in the prior reports[7,14,15]. 
In our study, survival was the worst in those with 
hepatotropic viral hepatitis as the underlying etiology, 
regardless of the status of liver transplantation. 
Patients with autoimmune hepatitis induced hepatic 
necrosis had the best transplant-free survival and those 
with DILI had the best survival after transplantation. It 
is not entirely clear why different causes may lead to 
different survival from our study. One might speculate 
that differences in patient age, availability of effective 
therapeutic options, or preexisting co-morbidities 
might play a role in prognosis. In our study, the median 
age for those with massive hepatic necrosis was 49, 
43, 48, and 44 years in autoimmune hepatitis, DILI, 
viral hepatitis, and unknown groups, respectively 
(Supplement 1). This finding demonstrates a lack of 
correlation between age and prognosis in the setting 
of substantial hepatic necrosis, although age has been 
suggested as playing a role in Hanau’s study[7]. In 
our study, the autoimmune hepatitis group had the 
greatest median age, and yet had the best overall 
survival . It is likely that effective therapeutic agents in 
autoimmune hepatitis might play a role in explaining 
why transplant-free survival is better when compared 
with other etiologies. However, due to the small 
number of cases in each of the substratified groups, 
no definitive conclusions can be drawn and further 
investigation seems warranted.
Bacterial infections and ascites were present 
more frequently in patients with a higher extent of 
hepatic necrosis. Mean INR for the patients with 
higher percentages of hepatic necrosis were also 
higher than in patients with a smaller percentage of 
necrosis. However none of these trends were found 
to be statistically significant. It is likely that a larger 
study may be able to identify a statistically significant 
association between these individual parameters.
Hepatic encephalopathy is present more frequently 
in the patients with massive necrosis. However, the 
incidence seems low in our study (19.2%). The re-
latively low incidence of encephalopathy might reflect 
the characteristics of the study cohort in our institution. 
The lack of a clear statistically significant association 
between extent of necrosis and encephalopathy is 
likely due to the relatively low number of patients in 
our study. In patients with hepatic encephalopathy 
and massive necrosis, the prognosis is extremely 
miserable. The only patient with encephalopathy 
who survived received a liver transplant. This finding 
suggests that encephalopathy due to hepatic necrosis 
may be associated with increased mortality. It also 
suggests that liver transplantation may be useful in this 
setting[16-20].
In conclusion, accurate histopathological evalu-
ation in patients with fulminant liver failure is useful. 
However, more research with a larger number of 
patients is required to truly identify any significant 
associations between the extent of hepatic necrosis 
and prognosis. The significance of liver biopsy is not 
limited to identifying or confirming the etiology; it is 
also a valuable tool in the assessment of prognosis 
and management decisions in regard to liver trans-
plantation. As demonstrated, the percentage of liver 
necrosis in an adequate liver biopsy is a prognostic 
indicator of survival. More than 75% hepatic necrosis 
is associated with substantial transplant-free mortality, 
thus massive hepatic necrosis is worth considering 
as an indicator for liver transplantation. Importantly, 
survival is associated with etiology with the worst in 
those with hepatotropic viral hepatitis even after liver 
transplantation. Taken together, assessing the extent 
of hepatic necrosis and its underlying etiology can aid 
in screening candidates who may benefit most from 
liver transplantation, a lifesaving but expensive and 
high risk procedure. Early identification of transplant 
candidates is critical in optimizing the utilization of 
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resources.
COMMENTS
Background
Patients with fulminant hepatic failure often receive liver biopsies as part of the 
clinical work-up. In many instances, extensive hepatic necrosis is identified. The 
significance of extensive hepatic necrosis within a liver biopsy, as it relates to 
patient prognosis or treatment decisions, has not been well described.
Research frontiers
To our knowledge, no new studies addressing the significance of biopsy proven 
hepatic necrosis as it relates to patient prognosis have been published for over 
twenty years. The objective of our study was to identify what associations if any 
exist between hepatic necrosis, patient clinical characteristics, and survival.
Innovations and breakthroughs
This study shows trends suggesting that the extent of hepatic necrosis is 
associated with poorer patient survival. Further, we noticed a trend that 
patients who undergo liver transplantation tend to have a longer survival time. 
Additionally, higher extents of hepatic necrosis typically showed trends with 
clinical factors such as higher mean INR, and increased frequency of ascites 
or bacterial infections. While these trends all seemed to be present within our 
study, no statistical significance was identified, likely due to the small size of our 
study (in spite of us having the largest number of cases to date).
Applications
The trends evident within our study may provide future investigators with a 
starting point for their inquiries into how hepatic necrosis may play a role in 
patient management.
Terminology
Fulminant liver failure is clinically characterized by an abrupt onset of jaundice 
and liver dysfunction with subsequent development of encephalopathy and 
coagulopathy in patients with or without preexisting liver disease. Hepatic 
necrosis is defined as death of hepatocytes, which maybe single cell, multiple 
cells in piecemeal, focal, multifocal, submassive or massive. Submassive 
hepatic necrosis is defined as necrosis involving 26%-75% of the parenchymal 
volume, while massive necrosis involves more than 75%. 
Peer-review
This paper evaluated if any association existed between the extent of hepatic 
necrosis and patient survival through observing the data resulted from 37 
patients with fulminant liver failure, whose liver biopsy exhibited substantial 
necrosis. It was found that transplant-free survival was worse in patients with 
a higher extent of necrosis (40%, 71.4% and 100% in groups with necrosis of 
76%-100%, 51%-75% and 26%-50%, respectively). So, the author concluded 
that adequate liver biopsy with more than 75% necrosis is associated with 
significant transplant-free mortality that is critical in predicting survival. This 
study has some scientific and clinic significances.
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